• Merck disclosed first Phase 2b results for tulisokibart in moderate-to-severe hidradenitis suppurativa, slated for presentation at EADV 2026.
• The trial met the main efficacy goal, showing patients on higher-dose regimens were more likely to improve than on placebo.
• Key secondary measures also trended in favor of treatment, including deeper clinical responses and better patient-reported quality of life.
• Safety looked broadly comparable with placebo, with serious adverse events uncommon and no serious or opportunistic infections reported.
• Merck plans to move the drug into Phase 3 in hidradenitis suppurativa, expanding its anti-TL1A program beyond inflammatory bowel disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609300815BIZWIRE_USPR_____20260930_BW948161) on September 30, 2026, and is solely responsible for the information contained therein.